Experimental mRNA Vaccine Offers Hope for Pancreatic Cancer Patients
Donna Gustafson, a 72-year-old grandmother from New Jersey, has become cancer-free after receiving an experimental mRNA vaccine for pancreatic cancer at Memorial Sloan Kettering Cancer Center. The vaccine, which is personalized using the patient's own tumor, aims to teach the immune system to target specific cancer cells. Gustafson was the first to receive this treatment, which included eight infusions and a booster following chemotherapy. Her case is part of a Phase 1 trial involving 16 patients, with half showing a measurable response. The vaccine's success in Gustafson's case is being presented at a major cancer conference, highlighting its potential to change treatment outcomes for one of the deadliest cancers. 
